Vr Adviser 13F annual report
Vr Adviser is an investment fund managing more than $2.1 trillion ran by Sherman Souther. There are currently 38 companies in Mr. Souther’s portfolio. The largest investments include Apogee Therapeutics Inc and 4d Molecular Therapeutics In, together worth $705 billion.
$2.1 trillion Assets Under Management (AUM)
As of 8th May 2024, Vr Adviser’s top holding is 8,493,321 shares of Apogee Therapeutics Inc currently worth over $564 billion and making up 26.8% of the portfolio value.
In addition, the fund holds 4,400,000 shares of 4d Molecular Therapeutics In worth $140 billion.
The third-largest holding is Ocular Therapeutix Inc worth $116 billion and the next is Spyre Therapeutics Inc worth $82.4 billion, with 2,171,782 shares owned.
Currently, Vr Adviser's portfolio is worth at least $2.1 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Vr Adviser
The Vr Adviser office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Sherman Souther serves as the Authorized Signatory at Vr Adviser.
Recent trades
In the most recent 13F filing, Vr Adviser revealed that it had opened a new position in
Apogee Therapeutics Inc and bought 8,493,321 shares worth $564 billion.
The investment fund also strengthened its position in Merus N.V by buying
564,000 additional shares.
This makes their stake in Merus N.V total 1,790,214 shares worth $80.6 billion.
Merus N.V soared 113.6% in the past year.
On the other hand, there are companies that Vr Adviser is getting rid of from its portfolio.
Vr Adviser closed its position in Aclaris Therapeutics Inc on 15th May 2024.
It sold the previously owned 4,563,962 shares for $71.9 billion.
Sherman Souther also disclosed a decreased stake in Cabaletta Bio Inc by 0.2%.
This leaves the value of the investment at $26.7 billion and 1,563,952 shares.
One of the largest hedge funds
The two most similar investment funds to Vr Adviser are Chilton Capital Management and Fj Investments. They manage $2.1 trillion and $2.1 trillion respectively.
Sherman Souther investment strategy
Vr Adviser’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 36.6% of
the total portfolio value.
The fund focuses on investments in the United States as
47.4% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
21% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $334 million.
The complete list of Vr Adviser trades based on 13F SEC filings
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Apogee Therapeutics Inc |
Opened
8,493,321
|
$564,381,180,000 | 26.85% |
| 4d Molecular Therapeutics In |
Opened
4,400,000
|
$140,184,000,000 | 6.67% |
| Ocular Therapeutix Inc |
Opened
12,762,462
|
$116,138,404,000 | 5.52% |
| Spyre Therapeutics Inc |
Opened
2,171,782
|
$82,375,691,000 | 3.92% |
| Merus N.V |
46.00%
1,790,214
|
$80,613,336,000 | 3.83% |
| Pharvaris N V |
Opened
3,395,606
|
$78,472,455,000 | 3.73% |
| KalVista Pharmaceuticals Inc |
114.28%
6,249,731
|
$74,121,810,000 | 3.53% |
| Aclaris Therapeutics Inc |
Closed
4,563,962
|
$71,882,402,000 | |
| Enliven Therapeutics Inc |
Opened
4,026,331
|
$70,823,162,000 | 3.37% |
| Viridian Therapeutics Inc |
43.81%
3,882,671
|
$67,985,569,000 | 3.23% |
| Dianthus Therapeutics Inc |
Opened
2,094,373
|
$62,831,190,000 | 2.99% |
| Dyne Therapeutics, Inc. |
Opened
2,173,913
|
$61,717,390,000 | 2.94% |
| Applied Therapeutics, Inc. |
Opened
9,075,000
|
$61,710,000,000 | 2.94% |
| Oric Pharmaceuticals, Inc. |
Opened
4,394,527
|
$60,424,746,000 | 2.87% |
| Axsome Therapeutics Inc |
Closed
670,718
|
$51,732,479,000 | |
| Astria Therapeutics Inc |
Opened
3,608,645
|
$50,791,678,000 | 2.42% |
| Mersana Therapeutics Inc |
Opened
11,328,000
|
$50,749,440,000 | 2.41% |
| Engene Holdings Inc |
Opened
2,565,841
|
$43,491,005,000 | 2.07% |
| Praxis Precision Medicines I |
Opened
706,126
|
$43,087,809,000 | 2.05% |
| Hillevax Inc |
Opened
2,075,000
|
$34,507,250,000 | 1.64% |
| Cogent Biosciences, Inc. |
27.02%
5,129,167
|
$34,468,002,000 | 1.64% |
| Gh Research Plc |
Closed
3,517,125
|
$34,186,455,000 | |
| Edgewise Therapeutics Inc |
Opened
1,818,182
|
$33,163,640,000 | 1.58% |
| Dbv Technologies S A |
Closed
9,300,000
|
$29,257,800,000 | |
| Cabaletta Bio Inc |
17.48%
1,563,952
|
$26,681,021,000 | 1.27% |
| Arvinas Inc |
Opened
627,788
|
$25,915,089,000 | 1.23% |
| Taysha Gene Therapies, Inc. |
Opened
9,000,000
|
$25,830,000,000 | 1.23% |
| Dice Therapeutics Inc |
Closed
819,000
|
$25,552,800,000 | |
| Aquestive Therapeutics Inc |
Opened
5,555,555
|
$23,666,664,000 | 1.13% |
| Terns Pharmaceuticals Inc |
8.03%
3,410,058
|
$22,369,980,000 | 1.06% |
| Adverum Biotechnologies Inc |
Opened
1,556,419
|
$22,007,765,000 | 1.05% |
| Aerovate Therapeutics Inc |
Closed
747,869
|
$21,912,562,000 | |
| Celcuity Inc |
53.93%
970,000
|
$20,952,000,000 | 1.00% |
| Pliant Therapeutics, Inc. |
Closed
1,080,000
|
$20,876,400,000 | |
| Novavax, Inc. |
Closed
1,879,894
|
$19,325,310,000 | |
| Abivax Sa |
Opened
1,345,780
|
$19,244,654,000 | 0.92% |
| Immatics N.v |
Opened
1,750,000
|
$18,392,500,000 | 0.87% |
| Annexon Inc |
Closed
3,220,050
|
$16,647,659,000 | |
| Vectivbio Hldg Ag |
Closed
1,866,000
|
$16,168,890,000 | |
| Lyra Therapeutics, Inc. |
178.75%
2,576,093
|
$16,023,298,000 | 0.76% |
| Cg Oncology Inc |
Opened
350,000
|
$15,365,000,000 | 0.73% |
| Century Therapeutics Inc |
Opened
3,405,133
|
$14,233,456,000 | 0.68% |
| Provention Bio, Inc. |
Closed
1,118,653
|
$11,824,162,000 | |
| Trevi Therapeutics, Inc. |
12.22%
3,422,675
|
$11,808,229,000 | 0.56% |
| Savara Inc |
Closed
6,351,531
|
$9,844,873,000 | |
| Milestone Pharmaceuticals In |
Closed
2,208,812
|
$8,746,896,000 | |
| Tenaya Therapeutics Inc |
Opened
1,555,556
|
$8,135,558,000 | 0.39% |
| Lianbio |
Closed
4,793,047
|
$7,860,597,000 | |
| Mineralys Therapeutics Inc |
Opened
555,554
|
$7,172,202,000 | 0.34% |
| Marinus Pharmaceuticals Inc |
Closed
1,770,705
|
$7,047,406,000 | |
| Acelyrin Inc |
Opened
937,113
|
$6,325,513,000 | 0.30% |
| EyePoint Pharmaceuticals Inc |
Opened
250,000
|
$5,167,500,000 | 0.25% |
| Fulcrum Therapeutics Inc |
Closed
447,326
|
$3,256,533,000 | |
| Inozyme Pharma, Inc. |
Closed
2,709,987
|
$2,845,486,000 | |
| Atyr Pharma Inc |
Closed
1,171,436
|
$2,565,445,000 | |
| Affimed N.V. |
Closed
1,428,571
|
$1,771,428,000 | |
| Rallybio Corp |
Closed
268,532
|
$1,764,255,000 | |
| Olema Pharmaceuticals, Inc. |
Opened
77,042
|
$872,115,000 | 0.04% |
| No transactions found | |||
| Showing first 500 out of 58 holdings | |||
Hedge funds similar to Vr Adviser
- North Star Asset Management Inc
- Covea Finance
- Amazon Com Inc
- Oversea-chinese Banking Corp Ltd
- Sand Hill Global Advisors
- Fj Investments
- Chilton Capital Management
- Silvant Capital Management
- Summit Partners Public Asset Management
- Laird Norton Wetherby Wealth Management
- Kimmeridge Management
- Paradigm Capital Management Inc/ny
- Plancorp
- Cx Institutional